Jasper Therapeutics Inc. (JSPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -47,884 | -30,340 | -14,260 | -37,685 | -24,474 |
| Depreciation Amortization | 825 | 549 | 274 | 975 | 702 |
| Accounts receivable | 663 | 663 | 663 | -663 | 0 |
| Accounts payable and accrued liabilities | 1,488 | -187 | 2,078 | -2,151 | -802 |
| Other Working Capital | 6,526 | 2,406 | 946 | -649 | 522 |
| Other Operating Activity | 2,794 | 3,302 | -36 | -5,685 | -9,160 |
| Operating Cash Flow | $-35,588 | $-23,607 | $-10,335 | $-45,858 | $-33,212 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -37 | -37 | -26 | -576 | -494 |
| Investing Cash Flow | $-37 | $-37 | $-26 | $-576 | $-494 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 101,903 | 101,867 | 101,511 | 55 | 27 |
| Other Financing Activity | -661 | -661 | 0 | 0 | 0 |
| Financing Cash Flow | $101,242 | $101,206 | $101,511 | $55 | $27 |
| Beginning Cash Position | 38,667 | 38,667 | 38,667 | 85,046 | 85,046 |
| End Cash Position | 104,284 | 116,229 | 129,817 | 38,667 | 51,367 |
| Net Cash Flow | $65,617 | $77,562 | $91,150 | $-46,379 | $-33,679 |
| Free Cash Flow | |||||
| Operating Cash Flow | -35,588 | -23,607 | -10,335 | -45,858 | -33,212 |
| Capital Expenditure | -37 | -37 | -26 | -576 | -494 |
| Free Cash Flow | -35,625 | -23,644 | -10,361 | -46,434 | -33,706 |